Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S

被引：0
|
作者：
Osoegawa, A. [1 ]
Hashimoto, T. [1 ]
Takumi, Y. [1 ]
Kobayashi, R. [1 ]
Miyawaki, M. [1 ]
Takeuchi, H. [1 ]
Okamoto, T. [1 ]
Sugio, K. [1 ]
机构：
[1] Oita Univ, Fac Med, Dept Thorac & Breast Surg, Yufu, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Acquired resistance; EGFR-TKI; PTEN;
D O I：
10.1016/j.jtho.2017.09.1568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-039
引用
收藏
页码：S2251 / S2251
页数：1
相关论文
共 50 条
  • [31] Acquired Resistance to Afatinib in Non-Small Cell Lung Cancer with EGFR G719X Mutation
    Harada, T.
    Futamura, S.
    Inoue, Y.
    Sawada, R.
    Okuda, T.
    Kagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S687 - S687
  • [32] The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
    Wang, Yubo
    Tian, Panwen
    Xia, Lei
    Li, Li
    Han, Rui
    Zhu, Mengxiao
    Lizaso, Analyn
    Qin, Tian
    Li, Min
    Yu, Bing
    Mao, Xinru
    Han Han-Zhang
    He, Yong
    LUNG CANCER, 2020, 146 : 165 - 173
  • [33] Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
    Takeda, Masayuki
    Okamoto, Isamu
    Tsurutani, Junji
    Oiso, Naoki
    Kawada, Akira
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 528 - 533
  • [34] Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
    Imamura, Fumio
    Inoue, Takako
    Kunimasa, Kei
    Kubota, Aki
    Kuhara, Hanako
    Tamiya, Motohiro
    Nishino, Kazumi
    Kimura, Madoka
    Kuno, Kika
    Kawachi, Hayato
    Kumagai, Toru
    LUNG CANCER MANAGEMENT, 2020, 9 (02)
  • [35] Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Okamoto, Kunio
    Fumita, Soichi
    Terashima, Masato
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    LUNG CANCER, 2015, 88 (01) : 16 - 23
  • [36] Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
    Nishihara, Shigetoshi
    Yamaoka, Toshimitsu
    Ishikawa, Fumihiro
    Ohmori, Tohru
    Ando, Koichi
    Kusumoto, Sojiro
    Kishino, Yasunari
    Manabe, Ryo
    Hasebe, Yuki
    Sagara, Hironori
    Yoshida, Hitoshi
    Tsurutani, Junji
    CELLS, 2022, 11 (14)
  • [37] Identification of biomarkers, pathways, and therapeutic targets for EGFR-TKI resistance in NSCLC
    Zhu, Leilei
    Gao, Shanshan
    Zhao, Xianya
    Wang, Ying
    LIFE SCIENCE ALLIANCE, 2023, 6 (12)
  • [38] EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice
    Higo, Hisao
    Ohashi, Kadoaki
    Makimoto, Go
    Nishii, Kazuya
    Kudo, Kenichiro
    Kayatani, Hiroe
    Watanabe, Hiromi
    Kano, Hirohisa
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    LUNG CANCER, 2019, 136 : 86 - 93
  • [39] EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis
    Xia, X.
    Guo, M.
    He, J.
    Liang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S382 - S382
  • [40] Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
    Zhou, Yinxue
    Wu, Tingyu
    Sun, Jiaxing
    Bi, Huanhuan
    Xiao, Yuting
    Shao, Yanmei
    Han, Weizhong
    Wang, Hongmei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4327 - 4343
12345